Comparison of utility measures and their relationship with other health status measures in 1041 patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 69, Issue 10, 2010, Pages 1762-1767

  Lillegraven, Siri ^a   Kristiansen, Ivar Sønbø ^b,c   Kvien, Tore K ^a  

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; DISEASE DURATION; GROUPS BY AGE; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH CARE UTILIZATION; HEALTH EDUCATION; HEALTH STATUS; HUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SEX DIFFERENCE; VISUAL ANALOG SCALE; ADOLESCENT; ARTHRITIS, RHEUMATOID; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DISABILITY; ECONOMICS; FEMALE; HEALTH CARE PLANNING; HEALTH STATUS INDICATOR; MALE; MIDDLE AGED; NORWAY; REGISTER; REPRODUCIBILITY; UTILIZATION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; DISABILITY EVALUATION; FEMALE; HEALTH RESOURCES; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; NORWAY; REGISTRIES; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 77957257578     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.124099     Document Type: Article

References (43)

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358:903-11.
2. Ødegård S, Finset A, Kvien TK, et al. Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register. Scand J Rheumatol 2005;34:441-7.
3. Dickens C, Creed F. The burden of depression in patients with rheumatoid arthritis. Rheumatology (Oxford) 2001;40:1327-30.
4. Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:iii-iv, xi-xiii, 1-229.
5. Neumann PJ, Goldie SJ, Weinstein MC. Preference-based measures in economic evaluation in health care. Annu Rev Public Health 2000;21:587-611. (Pubitemid 30480336)
6. Kernick DP. Introduction to health economics for the medical practitioner. Postgrad Med J 2003;79:147-50.
7. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328-46.
8. Scott DL, Garrood T. Quality of life measures: use and abuse. Baillieres Best Pract Res Clin Rheumatol 2000;14:663-87.
9. Kvien TK, Uhlig T. Quality of life in rheumatoid arthritis. Scand J Rheumatol 2005;34:333-41.
10. Harrison MJ, Davies LM, Bansback NJ, et al. The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review. J Rheumatol 2008;35:592-602.
11. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 2005.
12. Conner-Spady B, Suarez-Almazor ME. Variation in the estimation of quality-adjusted life-years by different preference-based instruments. Med Care 2003;41:791-801.
13. Marra CA, Esdaile JM, Guh D, et al. A comparison of four indirect methods of assessing utility values in rheumatoid arthritis. Med Care 2004;42:1125-31.
14. Marra CA, Rashidi AA, Guh D, et al. Are indirect utility measures reliable and responsive in rheumatoid arthritis patients? Qual Life Res 2005;14:1333-44.
15. Kvien TK, Uhlig T. The Oslo experience with arthritis registries. Clin Exp Rheumatol 2003;21(Suppl 31):S118-22.
16. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
17. Uhlig T, Kvien TK, Glennås A, et al. The incidence and severity of rheumatoid arthritis, results from a county register in Oslo, Norway. J Rheumatol 1998;25:1078-84. (Pubitemid 28350879)
18. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes 2003;1:20.
19. Pincus T, Summey JA, Soraci SA Jr, et al. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983;26:1346-53.
20. Meenan RF, Mason JH, Anderson JJ, et al. AIMS2. The content and properties of a revised and expanded Arthritis Impact Measurement Scales Health Status Questionnaire. Arthritis Rheum 1992;35:1-10.
21. Sintonen H. The 15D instrument of health-related quality of life: properties and applications. Ann Med 2001;33:328-36. (Pubitemid 32675373)
22. Sintonen H. The 15-D Measure of Health Related Quality of Life: Reliability, Validity and Sensitivity of Its Health State Descriptive System. Working Paper 41, 1994.
23. Linde L, Sørensen J, Ostergaard M, et al. Health-related quality of life: validity, reliability, and responsiveness of SF-36, 15D, EQ-5D [corrected] RAQoL, and HAQ in patients with rheumatoid arthritis. J Rheumatol 2008;35:1528-37.
24. Laas K, Roine R, Räsänen P, et al. Health-related quality of life in patients with common rheumatic diseases referred to a university clinic. Rheumatol Int 2009;29:267-73.
25. EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
26. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53-72.
27. Greiner W, Weijnen T, Nieuwenhuizen M, et al. A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ 2003;4:222-31.
28. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92.
29. Walters SJ, Brazier JE. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes 2003;1:4.
30. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.
31. Brazier J, Roberts J, Tsuchiya A, et al. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004;13:873-84.
32. Harrison MJ, Lunt M, Verstappen SM, et al. Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis. Health Qual Life Outcomes 2010;8:21.
33. Bansback N, Marra C, Tsuchiya A, et al. Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis. Arthritis Rheum 2007;57:963-71.
34. Hurst NP, Kind P, Ruta D, et al. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997;36:551-9. (Pubitemid 27344490)
35. Brennan A, Bansback N, Reynolds A, et al. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (Oxford) 2004;43:62-72.
36. Gülfe A, Kristensen LE, Saxne T, et al. Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden. Ann Rheum Dis 2010;69:352-7.
37. van den Hout WB, Goekoop-Ruiterman YP, Allaart CF, et al. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2009;61:291-9.
38. Marra CA, Marion SA, Guh DP, et al. Not all "quality-adjusted life years" are equal. J Clin Epidemiol 2007;60:616-24.
39. Harrison MJ, Davies LM, Bansback NJ, et al. Why do patients with inflammatory arthritis often score states "worse than death" on the EQ-5D? An Investigation of the EQ-5D classification system. Value Health 2009;12:1026-34.
40. Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 2005;23(Suppl 39):S14-18.
41. Sivas F, Barça N, Onder M, et al. The relation between joint erosion and generalized osteoporosis and disease activity in patients with rheumatoid arthritis. Rheumatol Int 2006;26:896-9.
42. Brauer CA, Rosen AB, Greenberg D, et al. Trends in the measurement of health utilities in published cost-utility analyses. Value Health 2006;9:213-18. (Pubitemid 44126775)
43. Bansback NJ, Regier DA, Ara R, et al. An overview of economic evaluations for drugs used in rheumatoid arthritis: focus on tumour necrosis factor-alpha antagonists. Drugs 2005;65:473-96. (Pubitemid 40469553)